CA-BELKIN
7.6.2022 18:02:05 CEST | Business Wire | Press release
Belkin , a global consumer electronics leader, today announces three new additions to its growing SOUNDFORM audio portfolio – the SOUNDFORM Immerse Noise Cancelling Earbuds, the SOUNDFORM Play True Wireless Earbuds, and SOUNDFORM Nano Wireless Earbuds for Kids. The new SOUNDFORM solutions fill out Belkin’s vast true wireless audio collection, offering wireless earbuds for wide age ranges and at various price points.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005084/en/
“Since launching the Belkin SOUNDFORM™ audio line just a few years ago, we introduced a variety of innovative audio solutions ranging from award-winning premium smart speakers to popular kids' headphones,” says Melody Tecson, senior director of product management, Belkin. “Our audio team has deep expertise in the acoustic industry and delivers high quality true wireless earbud solutions that will complement day-to-day activities from working out, taking work calls, or studying at home.”
SOUNDFORM™ Immerse Noise Cancelling Earbuds
Announced earlier this year at CES 2022, the SOUNDFORM Immerse Noise Cancelling Earbuds are Belkin’s top-of-the-line audio solution designed for true audiophiles who value a feature-rich solution and premium listening experience.
Key features:
- Hybrid ANC (Active Noise Cancellation) and 3 microphones per earbud filter and eliminate unwanted noise for clearer call quality and an ideal listening experience
- Hear-Thru mode enables users to adjust ambient sound levels so they can stay alert of their surroundings
- Multipoint connection offers seamless switching between multiple devices
- 12mm dual-layer dynamic drivers with neodymium magnets and aptX audio technology offer intensely vivid sounds and truly immersive audio moments
- 31 hours of battery life – 7 hours of playtime per charge for the earbuds, plus another 24 hours of battery in the wireless charging case for uninterrupted talking, listening, and streaming
- Locating capabilities with Apple Find My network to locate charging case, and Belkin Ping My Earbuds feature to locate earbuds
- Google Fast Pair allows Android phones to instantly connect with a simple tap
- Accompanying SOUNDFORM app provides advanced customization features such as personalized EQ settings and adjustable Hear-Thru levels
- Qi wireless charging case for quick and easy recharging
- IPX5-rated sweat and water resistance
- Black and White color options
SOUNDFORM™ Play True Wireless Earbuds
The SOUNDFORM Play True Wireless Earbuds are the next generation of Belkin’s original SOUNDFORM True Wireless Earbuds offering more features such as EQ presets, improved battery life, and four different color options at an affordable price.
Key features:
- Dual Beamforming technology with 2 microphones in each earbud reduces environmental noise and provides audio clarity on calls
- 38 hours of battery life — up to 8 hours of playtime for the earbuds, plus 30 hours in the charging case
- 3 touch-controllable EQ presets for personalized sound
- 6mm dynamic drivers deliver clear, dependable sound quality
- Fast USB-C charging fully charges case and buds in just 1.5 hours
- IPX5-rated sweat and water resistance
- Intuitive touch controls in both earbuds allows users to tap to skip tracks, answer calls and more
- Midnight, Cloud, Petal and Ocean color options
SOUNDFORM™ Nano Wireless Earbuds for Kids
The SOUNDFORM Nano Wireless Earbuds for Kids deliver safe, high-quality sound up to 85dB volume limit, all-day comfort and extended battery life so children ages 7+ can safely listen to audio. The SOUNDFORM Nano Wireless Earbuds join the SOUNDFORM Mini Wireless Headphones in Belkin’s audio collection specifically designed for kids.
Key features:
- Safe Sound for Kids 85dB volume limit protects young, sensitive hearing from loud sounds
- 5 different ear tip size options, including extra-extra small, assure a comfortable fit and premium listening experience for smaller ears
- 24 hours of battery life – up to 5 hours of non-stop playtime, with an additional 19 hours of battery life in the charging case
- 6mm dynamic driver in each earbud makes favorite songs come alive
- IPX5 water resistance keeps earbuds safe as kids splash through puddles, dash through light rain, and play carefree
- Case and earbuds are fully charged in just 2 hours with the included micro-USB cable
- Blue, Pink and White color options
Pricing and Availability
- The SOUNDFORM Immerse are now available to order for $179.99 USD on Belkin.com.
- The SOUNDFORM Play are now available to order for $59.99 USD on Belkin.com
- The SOUNDFORM Nano are now available to order for $49.99 USD on Belkin.com.
Imagery can be found HERE .
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity and audio solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people through technology whether at home, at work or on a new adventure. In 2018, Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remains forever inspired by people and the planet we live on.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005084/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom